Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26002619)

  • 1. Views of Australian Medical Oncologists Regarding the Use of Mismatch Repair Status to Assist Adjuvant Chemotherapy Recommendations for Patients With Early-Stage Colon Cancer.
    Loh KW; Michael M; Zalcberg JR; Jefford M
    Clin Colorectal Cancer; 2015 Sep; 14(3):192-7. PubMed ID: 26002619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
    Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
    Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the 12-gene colon cancer assay results on adjuvant treatment recommendations in patients with stage II colon cancer.
    Cartwright T; Chao C; Lee M; Lopatin M; Bentley T; Broder M; Chang E
    Curr Med Res Opin; 2014 Feb; 30(2):321-8. PubMed ID: 24127781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion?
    Sorscher S
    Curr Probl Cancer; 2018 Nov; 42(6):601-604. PubMed ID: 30119912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status on microsatellite instability, prognosis and adjuvant therapy in colon cancer: A nationwide survey of medical oncologists, colorectal surgeons and gastrointestinal pathologists.
    Toh JWT; Mahajan H; Chapuis P; Spring K
    Cancer Rep (Hoboken); 2021 Feb; 4(1):e1297. PubMed ID: 33030308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
    Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres.
    Grant M; Haydon A; Au L; Wilkins S; Oliva K; Segelov E; Antill Y; Carne P; Ranchod P; Polglase A; Farmer C; Chin M; Wale R; Simpson P; Bell S; Skinner S; McMurrick P; Shapiro J
    Int J Surg; 2018 Mar; 51():71-75. PubMed ID: 29367039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcome of adjuvant chemotherapy in deficient mismatch repair stage III colon cancer.
    Shaib WL; Zakka KM; Jiang R; Yan M; Alese OB; Akce M; Wu C; Behera M; El-Rayes BF
    Cancer; 2020 Sep; 126(18):4136-4147. PubMed ID: 32697360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer.
    Baek DW; Kang BW; Lee SJ; Kim HJ; Park SY; Park JS; Choi GS; Baek JH; Kim JG
    In Vivo; 2019; 33(2):649-657. PubMed ID: 30804154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
    Sargent DJ; Marsoni S; Monges G; Thibodeau SN; Labianca R; Hamilton SR; French AJ; Kabat B; Foster NR; Torri V; Ribic C; Grothey A; Moore M; Zaniboni A; Seitz JF; Sinicrope F; Gallinger S
    J Clin Oncol; 2010 Jul; 28(20):3219-26. PubMed ID: 20498393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Balaguer F; Sempere L; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Pons E; Payá A; Alenda C;
    Eur J Cancer; 2009 Feb; 45(3):365-73. PubMed ID: 18722765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the 12-Gene Colon Cancer Assay on Clinical Decision Making for Adjuvant Therapy in Stage II Colon Cancer Patients.
    Brenner B; Geva R; Rothney M; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Gluzman A; Purim O; Shacham-Shmueli E; Shulman K; Mishaeli M; Man S; Soussan-Gutman L; Tezcan H; Chao C; Shani A; Liebermann N
    Value Health; 2016 Jan; 19(1):82-7. PubMed ID: 26797240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
    Sinicrope FA; Foster NR; Yoon HH; Smyrk TC; Kim GP; Allegra CJ; Yothers G; Nikcevich DA; Sargent DJ
    J Clin Oncol; 2012 Feb; 30(4):406-12. PubMed ID: 22203756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer.
    Sinicrope FA
    Nat Rev Clin Oncol; 2010 Mar; 7(3):174-7. PubMed ID: 20190798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer.
    Benson AB; Schrag D; Somerfield MR; Cohen AM; Figueredo AT; Flynn PJ; Krzyzanowska MK; Maroun J; McAllister P; Van Cutsem E; Brouwers M; Charette M; Haller DG
    J Clin Oncol; 2004 Aug; 22(16):3408-19. PubMed ID: 15199089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
    Kim CA; Spratlin JL; Armstrong DE; Ghosh S; Mulder KE
    Clin Colorectal Cancer; 2014 Sep; 13(3):199-206. PubMed ID: 25088184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer.
    Krzyzanowska MK; Regan MM; Powell M; Earle CC; Weeks JC
    J Am Coll Surg; 2009 Feb; 208(2):202-9. PubMed ID: 19228531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.